



Pergamon

Bioorganic & Medicinal Chemistry Letters 8 (1998) 1903–1908

BIOORGANIC &
MEDICINAL CHEMISTRY
LETTERS

EFFICIENT SYNTHESIS OF 3'-GLYCOSYLATED LacNAc-BASED OLIGOSACCHARIDES

Yili Ding, Minrou Fukuda and Ole Hindsgaul*


*The Burnham Institute, La Jolla Cancer Research Center, 10901 North Torrey Pines Road,
La Jolla, CA 92037, U.S.A.*

Received 24 April 1998; accepted 11 June 1998

Abstract: LacNAc-based oligosaccharides, including sialyl-(2→3)-LacNAc, dimeric sialyl-(2→3)-LacNAc, trimeric sialyl-(2→3)-LacNAc, β -glucuronyl-(1→3)-LacNAc, and 3-sulfo- β -glucuronyl-(1→3)-LacNAc, were synthesized efficiently from a single protected LacNAc derivative having both OH-3' and 4' unprotected.

© 1998 Elsevier Science Ltd. All rights reserved.

Glycoscience has experienced a surge of interest in recent years as the biological roles of various carbohydrates have been elucidated.¹ This has led to an increased demand for oligosaccharides for biological studies.² Systematic studies on the binding of oligosaccharides with proteins have shown the general trend that the ligand bound to a protein is usually no larger than a tri- or tetrasaccharide. Many ligands are LacNAc derivatives,³ synthetic LacNAc-based oligosaccharides are therefore widely sought for biological studies. Here we report the efficient synthesis of five 3'-glycosylated LacNAc-based oligosaccharides: the parent LacNAc disaccharide **1**, sialyl-(2→3)-LacNAc trisaccharide **2**, dimeric sialyl-(2→3)-LacNAc tetrasaccharide **3**, trimeric sialyl-(2→3)-LacNAc pentasaccharide **4**, β -glucuronyl-(1→3)-LacNAc trisaccharide **5**, and 3-sulfo- β -glucuronyl-(1→3)-LacNAc trisaccharide **6**.



The hydrophobic octyl group was selected as the aglycone to simplify the isolation of the deblocked products on C-18 resin.⁴ Glycosylation of octyl 3,6-di-*O*-benzyl-2-acetamido-2-deoxy- β -D-glucopyranoside (**7**)⁵ with 2,3,4,6-tetra-*O*-acetyl- α -D-glucopyranosyl bromide (**8**) in the presence of AgOTf and 4 Å molecular sieves

afforded the desired β -linked disaccharide. Subsequent *O*-deacetylation provided disaccharide **9** in 71% yield (two steps). After hydrogenation, the LacNAc disaccharide **1** was obtained in 75% yield. Treatment of compound **9** with 2,2-dimethoxypropane in the presence of *p*-toluenesulfonic acid, followed by benzylation with BnBr/NaH and mildly acidic hydrolytic cleavage of the isopropylidene group afforded the suitably protected glycosyl acceptor **10** in 58% yield (three steps).




Figure 1: (a) Pd/C, H₂, MeOH, 75%; (b) 1. Me₂C(OMe)₂, CSA; 2. NaH, BnBr, *n*-Bu₄NI; 3. AcOH-H₂O (8:2), 52% (three steps).

From diol **10**, we synthesized sialyl LacNAc, dimeric sialyl LacNAc and trimeric sialyl LacNAc derivatives for use as substrates for polysialyltransferase.⁶ Glycosylation of **10** with the sialyl donor **11**⁷ in acetonitrile at -35 °C for 10 h, in the presence of NIS/TfOH and 3 Å powdered molecular sieves, afforded the desired α -glycoside **12** in 51% yield. *O*-Deacetylation with sodium methoxide in methanol, followed by saponification of the methyl ester and catalytic hydrogenolysis of the benzyl groups (10% Pd/C), yielded the 3'-sialyl LacNAc trisaccharide **2** in 65% yield (three steps).

Using similar procedures, condensation of **10** with the dimeric sialyl donor **13**⁸ gave the expected tetrasaccharide; after deacetylation and saponification, **14** was isolated in 25% yield (two steps). The ¹H NMR signals at 2.90 ppm (dd, 1H) and 2.70 ppm (dd, 1H) indicated α -glycoside formation. Catalytic hydrogenolysis (10% Pd/C) of the benzyl groups in methanol, followed by purification on Sephadex LH-20, yielded the 3'-dimeric sialyl LacNAc tetrasaccharide **3** in 50% yield.

Coupling the trimeric sialyl acid donor **15**⁹ with acceptor **10** for 24 h under the conditions described above, afforded the pentasaccharide. After deacetylation and saponification, pentasaccharide **16** was isolated in 20% yield (three steps). The ¹H NMR signals at 2.91 ppm (dd, 1H), 2.71 ppm (dd, 1H) and 2.55 ppm (dd, 1H) supported the α -glycosidic linkage. After hydrogenation on Pd/C (MeOH/AcOH, 2 days), the final 3'-trimeric sialyl LacNAc **4** was obtained in 40% yield after purification on Sephadex LH-20.

Sulfated and unsulfated β -glucuronyl-(1 \rightarrow 3)-LacNAc trisaccharides were required as substrates and standards in a study on the enzymatic sulfation of β -glucuronyl-(1 \rightarrow 3)-LacNAc derivatives.¹⁰ The glycosylation of **10** with glucuronyl imidate **17**¹¹ was performed at -20 °C in the presence of 0.15 equiv of BF₃/etherate and afforded the 1 \rightarrow 3 linked trisaccharide **18** in 51% yield. After acetylation, the signal for H-4 of the galactosyl




Figure 2: (a) NIS (2 equiv), TfOH (0.2 equiv), CH₃CN, 3 Å MS, -35 °C, 2 h, (51%); (b) 1. Pd/C, MeOH/AcOH (1:1), H₂; 2. MeONa/MeOH, 12 h; 3. NaOH/H₂O/MeOH, (1.-3.: 65%); (c) 1. NIS (3 equiv), TfOH (0.2 equiv), CH₃CN, 3 Å MS, -35 °C, 24 h; 2. MeONa/MeOH/H₂O, 24 h, (1.-2.: 25%); (d) Pd/C, MeOH/AcOH, H₂, (50%); (e) 1. NIS (3 equiv), TfOH (0.2 equiv), CH₃CN, 3 Å MS, -35 °C, 24 h; 2. MeONa/MeOH/H₂O, 24 h, (1.-2.: 20%); (f) Pd/C, MeOH/AcOH, H₂, (40%); (g) BF₃/ether (0.15 equiv), CH₂Cl₂, 4 Å MS, -20 °C, 4 h, (51%); (h) 1. NH₂NH₂.AcOH, EtOH, rt, 1 h; 2. SO₃.Et₃N, DMF, 40 °C, 12 h; 3. MeONa/MeOH/H₂O; 4. Pd/C, MeOH, H₂, (1.-4. 55%); (i) BF₃/ether (0.15 equiv), CH₂Cl₂, 4 Å MS, -20 °C, 2 h, (70%); (j) 1. MeONa/MeOH/H₂O; 2. Pd/C, MeOH, H₂, (1.-2. 45%).

moiety was shifted from 4.01 ppm (d, $J = 2.7$ Hz, 1H) to 4.79 ppm (d, $J = 2.7$ Hz, 1H), confirming the 1→3 linkage. Selective removal of the levulinoyl group was achieved with hydrazine-monoacetate. Treatment of the product with excess sulfur trioxide trimethylamine complex in DMF at 40 °C followed by deacetylation with methanolic sodium methoxide, saponification of the methyl ester with sodium hydroxide and catalytic hydrogenolysis (Pd/C, 10%) afforded 3-*O*-sulfo- β -glucuronyl-(1→3)-LacNAc **6** in 55% yield after purification on Sephadex LH-20 (four steps). Deprotection of **18** by hydrogenation, deacetylation and saponification gave β -glucuronyl-(1→3)-LacNAc **5** in 62% yield (three steps).

The perbenzoyl glucuronyl donor **19** was prepared from methyl [2-(trimethylsilyl)ethyl β -D-glucopyranoside]uronate¹¹ in 70% yield by benzylation, removal of the 2-(trimethylsilyl) ether group, and formation of the trichloroacetimidate. Glycosylation of **10** with **19** in the presence of BF₃/etherate at -20 °C afforded the 1→3 linked β -glycoside **20** in 70% yield. After catalytic hydrogenolysis (10% Pd/C) of the benzyl groups in methanol, *O*-debenzylation with sodium methoxide in methanol, and subsequent saponification of methyl ester group with sodium hydroxide, the trisaccharide **5** was obtained in 45% yield (three steps).

In conclusion, the partially protected LacNAc diol **10** was found to be an efficient acceptor for the synthesis of biologically important 3'-glycosylated LacNAc-based oligosaccharides.

Acknowledgment

This work was supported by P01CA 71932 from The National Institutes of Health.

References and notes

1. Fukuda, M. in *Molecular Glycobiology*; Fukuda, M.; Hindsgaul, O., Eds.; IRL: Oxford, 1994; pp 1-52.
2. Lemieux, R. U. *Chem. Soc. Rev.* **1989**, *18*, 347.
3. Bundle, D. R.; Baumann, H.; Brisson, J. R.; Gagne, S. M.; Zdanov, V.; Cygler, M. *Biochemistry* **1994**, *33*, 5183.
4. Palcic, M. M.; Heerze, L. D.; Pierce, M.; Hindsgaul, O. *Carbohydr. Res.* **1988**, *5*, 49.
5. Malet, C.; Hindsgaul, O. *Carbohydr. Res.* **1997**, *303*, 567.
6. Fukuda, M.; Ding, Y.; Hindsgaul, O. unpublished results.
7. Roy, R.; Andersson, F. O.; Letellier, M. *Tetrahron Lett.* **1992**, *33*, 6053.

8. Ishida, H. K.; Ohta, Y.; Tsukada, Y.; Kiso, M.; Hasegawa, A. *Carbohydr. Res.* **1993**, *246*, 75.
9. Ishida, H. K.; Ishida, H.; Kiso, M.; Hasegawa, A. *J. Carbohydr. Chem.* **1994**, *13*, 655.
10. Ong, E.; Yeh, J. C.; Ding, Y.; Hindsgaul, O.; Fukuda, M. *J. Biol. Chem.* **1998**, *273*, 5190.
11. Isogai, Y.; Kawase, T.; Ishida, H.; Kiso, M.; Hasegawa, A. *J. Carbohydr. Chem.* **1996**, *15*, 1001.

Spectral data for selected new compounds:

1, ^1H NMR (300 MHz, CD_3OD): δ 4.38 (1H, $J = 7.6$ Hz, H-1), 4.40 (1H, $J = 7.6$ Hz, H-1'), 1.95 (s, 3H, NHCOCH_3), 0.88 (t, 3H, $J = 6.6$ Hz, CH_3).

2, ^1H NMR (300 MHz, CD_3OD): δ 4.44 (d, 1H, $J = 7.8$ Hz, H-1), 4.36 (d, 1H, $J = 8.1$ Hz, H-1'), 4.04 (dd, 1H, $J_{3,2} = 9.6$ Hz, $J_{3,4'} = 3$ Hz, H-3'), 2.75 (dd, 1H, H-3''eq), 2.00 (s, 3H, NHCOCH_3), 1.95 (s, 3H, NHCOCH_3), 0.89 (t, 3H, $J = 6.6$ Hz, CH_3); ^{13}C NMR (300 MHz, CD_3OD): δ 102.9, 101.8, 100.9 (C-1, C-1' and C-1'').

3, ^1H NMR (300 MHz, CD_3OD): δ 4.44 (d, 1H, $J = 7.2$ Hz, H-1), 4.38 (d, 1H, $J = 8.0$ Hz, H-1'), 2.48 (m, 2H, H-3''eq and H-3'''eq), 2.02 (s, 6H, $2 \times \text{NHCOCH}_3$), 1.96 (s, 3H, NHCOCH_3), 0.90 (t, 3H, $J = 6.6$ Hz, CH_3); ESMS: m/z 1077 $[\text{M}]^+$.

4, ^1H NMR (500 MHz, CD_3OD): δ 4.40 (d, 1H, $J = 7.7$ Hz, H-1), 4.38 (d, 1H, $J = 8.0$ Hz, H-1') 2.89 (dd, 1H), 2.49 (dd, 1H), 2.45 (dd, 1H), 2.04 (s, 3H, NHCOCH_3), 2.03 (s, 3H, NHCOCH_3), 2.01 (s, 6H, $2 \times \text{NHCOCH}_3$), 0.89 (t, 3H, $J = 6.7$ Hz, CH_3); ESMS: m/z 1367 $[\text{M}]^+$.

5, ^1H NMR (300 MHz, CD_3OD): δ 4.68 (d, 1H, $J = 7.8$ Hz, H-1), 4.52 (d, 1H, $J = 7.6$ Hz, H-1'), 4.50 (d, 1H, $J = 7.0$ Hz, H-1''), 4.11 (d, 1H, $J < 1$ Hz, H-4'), 1.95 (s, 3H, NHCOCH_3), 0.89 (t, 3H, $J = 6.6$ Hz, CH_3); ^{13}C NMR (300 MHz, CD_3OD): δ 105.4, 105.4, 102.8 (C-1, C-1' and C-1''); ESMS: m/z 670 $[\text{M}]^+$.

6, ^1H NMR (300 MHz, CD_3OD): δ 4.65 (d, 1H, H-1), 4.49 (m, 2H, H-1' and H-1''), 4.30 (t, 1H, H-3''), 4.11 (d, 1H, $J < 1$ Hz, H-4''), 1.95 (s, 3H, NHCOCH_3), 0.89 (t, 3H, $J = 6.6$ Hz, CH_3); ^{13}C NMR (300 MHz, CD_3OD): δ 105.4, 105.3, 102.9 (C-1, C-1' and C-1''); ESMS: m/z 772 $[\text{M}]^+$.

9, ^1H NMR (300 MHz, CD_3OD): δ 4.45 (d, 1H, $J = 7.8$ Hz, H-1'), 4.39 (d, 1H, $J = 7.8$ Hz, H-1), 1.91 (s, 3H, NHCOCH_3), 0.88 (t, 3H, $J = 6.9$ Hz, CH_3); ^{13}C NMR (300 MHz, CD_3OD): δ 104.4, 102.8 (C-1 and C-1').

10, ^1H NMR (300 MHz, CD_3OD): δ 4.38 (d, 1H, $J = 7.2$ Hz, H-1), 4.38 (d, 1H, $J = 7.3$ Hz, H-1'), 1.90 (s, 3H, NHCOCH_3), 0.90 (s, 3H, $J = 6.6$ Hz, CH_3); ^{13}C NMR (300 MHz, CD_3OD): δ 104.3, 102.8 (C-1, C-1').

14, ^1H NMR (300 MHz, CD_3OD): δ 7.1–7.4 (m, 20H, $4\times\text{CH}_2\text{Ph}$), 2.64 (dd, 1H, H-3'eq), 2.59 (dd, 1H, H-3'''eq), 2.0 (s, 6H, $2\times\text{NHCOCH}_3$), 1.81 (s, 3H, NHCOCH_3), 0.90 (s, 3H, CH_3); ^{13}C NMR (300 MHz, CD_3OD): δ 104.9, 103.8, 103.0, 102.5 (C-1, C-1', C-2'' and C-2''').

16, ^1H NMR (300 MHz, CD_3OD): δ 7.1–7.4 (m, 20H, $4\times\text{CH}_2\text{Ph}$), 2.90 (dd, 1H, H-3'eq), 2.70 (dd, 1H, H-3'''eq), 2.58 (dd, 1H, H-3'''eq), 2.00 (s, 6H, $2\times\text{NHCOCH}_3$), 1.98 (s, 3H, NHCOCH_3), 1.80 (s, 3H, NHCOCH_3); 0.89 (t, 3H, $J = 6.6$ Hz, CH_3); ^{13}C NMR (300 MHz, CD_3OD): δ 104.0, 103.5, 103.0, 102.8, 102.2 (C-1, C-1', C-2'', C-2''' and C-2''').

18, ^1H NMR (300 MHz, CD_3OD): δ 5.59 (t, 1H, $J = 9.0$ Hz, H-2''), 5.31 (d, 1H, $J = 8.1$ Hz, H-1''), 5.21 (t, 1H, $J = 9.9$ Hz, H-3''), 5.12 (d, 1H, $J = 10.8$ Hz, H-4''), 4.59 (d, 1H, $J = 8.1$ Hz, H-1'), 4.43 (d, 1H, $J = 8.1$ Hz, H-1), 4.01 (d, 1H, $J = 2.7$ Hz, H-4'), 3.59 (s, 3H, OCH_3), 2.06 (s, 3H, COCH_3), 1.99 (s, 3H, OCOCH_3), 1.96 (s, 3H, NHCOCH_3), 0.89 (t, 3H, CH_3); ^{13}C NMR (300 MHz, CD_3OD): δ 102.51, 101.49, 99.34 (C-1, C-1' and C-1'').

20, ^1H NMR (300 MHz, CD_3OD): δ 6.03 (t, 1H, $J = 9.9$ Hz), 5.58 (t, 1H, $J = 9.0$ Hz), 5.57 (d, 1H, $J = 7.5$ Hz, H-1''), 5.13 (d, 1H, $J = 10.8$ Hz, H-5''), 4.60 (d, 1H, $J = 7.5$ Hz, H-1), 4.30 (d, 1H, $J = 7.5$ Hz, H-1'), 3.50 (s, 3H, OCH_3), 1.96 (s, 3H, NHCOCH_3), 0.88 (t, 3H, $J = 6.0$ Hz, CH_3); ^{13}C NMR (300 MHz, CD_3OD): δ 103.86, 102.99, 102.76 (C-1, C-1' and C-1'').